Drugs / HEV239
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03827395 | Apr 2019 → Aug 2020 | hepatitis E virus infection | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT01014845 | Aug 2007 → Oct 2017 | hepatitis E virus infection | Xiamen University | Completed | Met primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT02189603 | Jun 2014 → Dec 2015 | hepatitis E virus infection | Jun Zhang | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HEV239 | “Hepatitis E vaccine, containing 30mcg of HEV239 recombinant antigen adsorbed to alum adjuvant suspended in 0.5ml phosphate buffer, was given at 0, 1, 6m for three doses.” NCT02189603 ↗4“trial of 30 µg HEV-239 (Hecolin, Xiamen Innovax Biotech Company Limited, China) administered intramuscularly in healthy US adults aged 18-45 years.” PMID 38536442 ↗ Nov 2024 “a recombinant hepatitis E vaccine, HEV 239 (Hecolin; Xiamen Innovax Biotech, Xiamen, China)” PMID 20728932 ↗ Aug 2010 “Safety Study of Hepatitis E Vaccine (HEV239)” NCT03827395 ↗ |
| Known as | Hecolin | “trial of 30 µg HEV-239 (Hecolin, Xiamen Innovax Biotech Company Limited, China) administered intramuscularly in healthy US adults aged 18-45 years.” PMID 38536442 ↗ Nov 2024 |
| Known as | Hecolin(R) | “A Phase 1, Double-Blinded, Placebo Controlled, Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of HEV-239 (Hecolin(R)) in a Healthy US Adult Population” NCT03827395 ↗ |
| Modality | Vaccine | “a recombinant hepatitis E vaccine” PMID 20728932 ↗ Aug 2010 |
| Route | Intramuscular | “Intramuscularly given at 0, 1, 6m for three doses.” NCT01014845 ↗ |